Altre lingue Solasia Pharma K.K.

Azioni

4597

JP3436500007

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
26 ^JPY	+4,00%		+4,00%	-42,22%

2023	Solasia Pharma K.K. rivede le previsioni di utile consolidato per l'anno fiscale che terminerà il 31 dicembre 2023	CI
2023	Solasia Pharma riduce la perdita del nono mese grazie all'aumento delle entrate	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin	19/03
Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited	04/03
Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond	16/02
Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited	15/02
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	28/12
Solasia Pharma Narrows Nine-Month Loss as Revenue Gains	14/11
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023	13/11
Solasia Pharma K.K.(TSE:4597) dropped from S&P Global BMI Index	18/09/23
Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	10/08/23
Solasia Pharma K.K. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023	15/05/23
Solasia Pharma Teams Up with WEP Clinical to Supply Anti-Cancer Injection in Europe	21/03/23
Solasia Partners with WEP Clinical to Supply Darvias [Darvias Injection 135Mg] Under a Named Patient Program	20/03/23
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023	14/02/23
Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Study	28/11/22
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	25/11/22
An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. from ITOCHU Corporation.	22/11/22
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	14/11/22
Solasia Announces Summary of SP-04 PledOx Development Status	05/09/22
Solasia Launches Anticancer Injection Darvias	23/08/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Solasia Pharma K.K.

Azioni

4597

JP3436500007

Altre lingue

Filtri